RxDoctor Payments Data

Stewart Walther, MD

Cardiovascular Disease · Albuquerque, NMNPI 1366732117

Payments from drug & device makers

What this record shows

11 manufacturers reported payments, led by Abiomed at 51.6% of the total. Reporting peaked in 2022 at $1,065 and has fallen 81.3% since, to $200 in 2025.

$1,708in general payments, 2019–2025

Across 39 payments — averaging $43.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$881
  • AstraZeneca$260
  • Amgen$157
  • Heartflow, Inc.$149
  • Novartis$102
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$48
  • plus $111 from 5 others

What the payments were for

  • Travel & lodging$86451%
  • Food & beverage$84349%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,708 in reported general payments places this provider in the 60th percentile of 101 cardiovascular disease providers in New Mexico.

See all cardiovascular disease providers in New Mexico

Medicare billing

Part B allowed, 2024
$62,552
Medicare patients
579
Services billed
1,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban203$246,180
EliquisApixaban120$139,548
EntrestoSacubitril/Valsartan65$93,685
Repatha SureclickEvolocumab54$35,039
FarxigaDapagliflozin Propanediol26$27,219
Metoprolol Succinate303$5,704
DapagliflozinDapagliflozin Propanediol11$5,669
Atorvastatin Calcium300$4,174
Carvedilol160$2,202
Amiodarone Hcl28$1,653
Lisinopril129$1,544
Losartan Potassium107$1,372
Furosemide178$1,367
Flecainide Acetate28$1,322
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$1,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$102$93,68565 claims
AstraZenecaFarxiga$260$27,21926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 101 cardiovascular disease providers in New Mexico.

Other cardiovascular disease in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →